These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 22554766

  • 41. Revisiting the use of sPLA2-sensitive liposomes in cancer therapy.
    Pourhassan H, Clergeaud G, Hansen AE, Østrem RG, Fliedner FP, Melander F, Nielsen OL, O'Sullivan CK, Kjær A, Andresen TL.
    J Control Release; 2017 Sep 10; 261():163-173. PubMed ID: 28662900
    [Abstract] [Full Text] [Related]

  • 42. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S.
    Clin Cancer Res; 2003 Dec 15; 9(17):6551-9. PubMed ID: 14695160
    [Abstract] [Full Text] [Related]

  • 43. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
    Mori A, Wu SP, Han I, Khokhar AR, Perez-Soler R, Huang L.
    Cancer Chemother Pharmacol; 1996 Dec 15; 37(5):435-44. PubMed ID: 8599866
    [Abstract] [Full Text] [Related]

  • 44. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M, Farzaneh H, Badiee A, Golmohammadzadeh S, Sadri K, Jaafari MR.
    Eur J Pharm Sci; 2015 Dec 01; 80():66-73. PubMed ID: 26299343
    [Abstract] [Full Text] [Related]

  • 45. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S.
    J Control Release; 2012 Jun 10; 160(2):245-53. PubMed ID: 22134116
    [Abstract] [Full Text] [Related]

  • 46. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR, Gerberich JL, Nowotnik DP, Howell SB.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [Abstract] [Full Text] [Related]

  • 47. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.
    Cabral H, Nishiyama N, Kataoka K.
    J Control Release; 2007 Aug 28; 121(3):146-55. PubMed ID: 17628162
    [Abstract] [Full Text] [Related]

  • 48. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K, Kashiwagi M, Shiba S, Muroki K, Ohishi A, Doi Y, Ando H, Ishida T, Nagasawa K.
    Toxicol Appl Pharmacol; 2017 Dec 15; 337():76-84. PubMed ID: 29054682
    [Abstract] [Full Text] [Related]

  • 49. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.
    Anticancer Res; 2009 Jun 15; 29(6):2111-20. PubMed ID: 19528471
    [Abstract] [Full Text] [Related]

  • 50. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
    Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S.
    Adv Drug Deliv Rev; 2004 Apr 29; 56(8):1177-92. PubMed ID: 15094214
    [Abstract] [Full Text] [Related]

  • 51. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C, Cui J, Wang C, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Int J Pharm; 2008 Oct 01; 362(1-2):60-6. PubMed ID: 18598745
    [Abstract] [Full Text] [Related]

  • 52. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.
    J Pharm Pharmacol; 2005 Oct 01; 57(10):1279-87. PubMed ID: 16259756
    [Abstract] [Full Text] [Related]

  • 53. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ, Masin D, Cullis PR, Bally MB.
    J Pharmacol Exp Ther; 1997 Mar 01; 280(3):1319-27. PubMed ID: 9067319
    [Abstract] [Full Text] [Related]

  • 54. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
    Herringson TP, Altin JG.
    Int J Pharm; 2011 Jun 15; 411(1-2):206-14. PubMed ID: 21443937
    [Abstract] [Full Text] [Related]

  • 55. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Coimbra M, Banciu M, Fens MH, de Smet L, Cabaj M, Metselaar JM, Storm G, Schiffelers RM.
    J Control Release; 2010 Dec 20; 148(3):303-10. PubMed ID: 20869410
    [Abstract] [Full Text] [Related]

  • 56. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery.
    Tang J, Fu H, Kuang Q, Zhang L, Zhang Q, Liu Y, Ran R, Gao H, Zhang Z, He Q.
    J Drug Target; 2014 May 20; 22(4):313-26. PubMed ID: 24404866
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.
    Seguin J, Brullé L, Boyer R, Lu YM, Ramos Romano M, Touil YS, Scherman D, Bessodes M, Mignet N, Chabot GG.
    Int J Pharm; 2013 Feb 28; 444(1-2):146-54. PubMed ID: 23380621
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.